LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

Search

Charles River Laboratories International Inc

Chiusa

SettoreSettore sanitario

159.91 0.48

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

156.75

Massimo

163.05

Metriche Chiave

By Trading Economics

Entrata

-332M

-277M

Vendite

-11M

994M

Margine di Profitto

-27.816

Dipendenti

18,300

EBITDA

730K

198M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+29.36% upside

Dividendi

By Dow Jones

Utili prossimi

6 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-163M

7.8B

Apertura precedente

159.43

Chiusura precedente

159.91

Notizie sul Sentiment di mercato

By Acuity

50%

50%

169 / 349 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Charles River Laboratories International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

30 mar 2026, 23:15 UTC

Principali Notizie su Eventi

U.K. Shoppers Paid a Little More This Month But Worse May yet Lie Ahead

30 mar 2026, 22:36 UTC

Principali Notizie su Eventi

Australian Government Rules Out Boots on the Ground in the Middle East

30 mar 2026, 22:13 UTC

Acquisizioni, Fusioni, Takeovers

Sun Life Financial Agrees to Buy Bell Partners for $350 Million

30 mar 2026, 21:00 UTC

Utili

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment

30 mar 2026, 20:15 UTC

Principali Notizie su Eventi

Fed's Williams: Middle-East Developments Have Added Significant Economic Uncertainty

30 mar 2026, 23:40 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

30 mar 2026, 23:40 UTC

Discorsi di Mercato

Nikkei May Decline on Higher Energy Cost Concerns -- Market Talk

30 mar 2026, 23:36 UTC

Discorsi di Mercato

Gold Edges Lower Amid Divergent Signals on U.S.-Iran Talks -- Market Talk

30 mar 2026, 23:12 UTC

Discorsi di Mercato

Alcoa Earnings Outlook Boosted by Market Disruptions -- Market Talk

30 mar 2026, 22:49 UTC

Discorsi di Mercato

Fed's Williams: Core Inflation Forecast Is Little Changed -- Market Talk

30 mar 2026, 22:44 UTC

Discorsi di Mercato

Fed's Williams: Risks to Both Sides of Dual Mandate Higher -- Market Talk

30 mar 2026, 22:43 UTC

Discorsi di Mercato

Fed's Williams Says Focus Is on Inflation Expectations Being Well Anchored -- Market Talk

30 mar 2026, 22:42 UTC

Discorsi di Mercato

South32 Should Go for Growth, Says New Bull -- Market Talk

30 mar 2026, 22:18 UTC

Discorsi di Mercato

Paragon Care's Chances of Using Levy to Pass on Higher Costs `Close to Zero' -- Market Talk

30 mar 2026, 22:05 UTC

Discorsi di Mercato

Northern Star's New Bull Argues Case for Asset Sales -- Market Talk

30 mar 2026, 21:58 UTC

Acquisizioni, Fusioni, Takeovers

Sun Life Financial Agrees to Buy Bell Partners for $350M

30 mar 2026, 21:39 UTC

Acquisizioni, Fusioni, Takeovers

Sun Life Sees 1Q Charge to Net of C$236M From BGO, Crescent Deals

30 mar 2026, 21:38 UTC

Acquisizioni, Fusioni, Takeovers

Sun Life: Completes Remaining Equity Interest Purchases of BGO, Crescent Capital

30 mar 2026, 21:36 UTC

Acquisizioni, Fusioni, Takeovers

Sun Life to Buy Fully Bell Partners for $350M >SLF.T

30 mar 2026, 21:33 UTC

Acquisizioni, Fusioni, Takeovers

Unilever Shareholders Expected to Own Two-Thirds of New Food Entity, Sources Say -- WSJ

30 mar 2026, 21:33 UTC

Acquisizioni, Fusioni, Takeovers

Unilever Nears Deal to Create $60 Billion Food Giant With McCormick -- WSJ

30 mar 2026, 21:33 UTC

Acquisizioni, Fusioni, Takeovers

Deal Could Be Announced As Soon As Tuesday, Sources Say -- WSJ

30 mar 2026, 21:33 UTC

Acquisizioni, Fusioni, Takeovers

Unilever Nears Cash-and-Stock Deal to Combine Food Business With McCormick, Sources Say -- WSJ

30 mar 2026, 21:33 UTC

Acquisizioni, Fusioni, Takeovers

Deal Set to Value Combined Food Business At Around $60B Including Debt, Sources Say -- WSJ

30 mar 2026, 21:25 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

30 mar 2026, 21:25 UTC

Discorsi di Mercato

Warehouse Showing Cost Discipline But Margin Goal at Risk -- Market Talk

30 mar 2026, 21:03 UTC

Acquisizioni, Fusioni, Takeovers

Sun Life: Completes Equity Interest Purchases of BGO and Crescent Cap, Announces Acquisition of Bell Partners, a Multifamily Real Estate Investment Manager

30 mar 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

30 mar 2026, 20:09 UTC

Utili

This Stock Looks Like a Solid AI Bet -- and Wall Street Hasn't Noticed Yet -- Barrons.com

30 mar 2026, 20:00 UTC

Principali Notizie su Eventi

Fed's Williams: Middle-East Conflict 'Will Likely Boost Overall Inflation in Coming Months'

Confronto tra pari

Modifica del prezzo

Charles River Laboratories International Inc Previsione

Obiettivo di Prezzo

By TipRanks

29.36% in crescita

Previsioni per 12 mesi

Media 205.89 USD  29.36%

Alto 265 USD

Basso 175 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

8

Acquista

3

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

117.16 / 144.77Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

169 / 349 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat